Andrew Fein's questions to WAVE Life Sciences Ltd (WVE) leadership • Q2 2025
Question
Andrew Fein of H.C. Wainwright & Co. asked for takeaways from competitor data at the ADA conference and how it informs the WVE-007 strategy. For WVE-006, he relayed KOL feedback suggesting the importance of reaching ~22 micromolar of AAT and replicating an acute phase response.
Answer
President & CEO Paul Bolno responded that competitor data reinforces the importance of muscle preservation, an area where WVE-007 is designed to excel as a monotherapy. For WVE-006, he agreed with the KOLs, stating that RNA editing is designed to preserve the body's natural ability to mount an acute phase response, a key differentiator from protein replacement therapy. He noted this was a core part of the original thesis for using RNA editing in AATD.